HCPLive Network

Physicians Don’t Consider Costs When Ordering Imaging Tests

 
FRIDAY, Feb. 1 (HealthDay News) -- Physicians do not order fewer imaging tests if they are aware of the costs, according to a study published online Jan. 2 in the Journal of the American College of Radiology.

Daniel J. Durand, M.D., from Johns Hopkins University in Baltimore, Md., and colleagues identified the 10 most frequently ordered imaging tests in fiscal year 2007. No costs were displayed during a baseline period from Nov. 10, 2008, to May 9, 2009. Costs were displayed only for tests in the active group during a seasonally matched intervention period from Nov. 10, 2009, to May 9, 2010. At the conclusion of the study, the number of orders executed for all tests during both periods was compared.

The researchers found that there was no significant difference in the mean utilization change between the active group and the control group (2.8 ± 4.4 percent and −3.0 ± 5.5 percent, respectively; P = 0.10). For the active versus control group, there was no significant difference in the correlation between the cost of the test and the change in utilization. The study had 90 percent power to detect an 11.8 percent difference in mean relative utilization change between groups, on the basis of the observed standard deviations.

"Provider cost transparency alone did not influence inpatient imaging utilization or its associated costs in any significant fashion," the authors write. "Specifically, the large decreases in laboratory test utilization due to provider cost transparency reported previously were not found to generalize to inpatient imaging at a tertiary care academic hospital."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Researchers at Hong Kong University and the Wellcome Trust Sanger Institute have identified a link between the influenza A viruses’ genetic diversity and severity of the infection.
Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.
Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The immune system is the new focus of much work on traumatic brain injury (TBI). In a challenge to the paradigm that the blood brain barrier prevents harmful leukocytes from entering the brain, a Texas team tried to neutralize the impact of these cells. Peripheral lymphocytes are activated after TBI. They may then act as potential antigen presenting cells and get into the brain, causing cells there to degenerate.
Black women undergoing in vitro fertilization are only about half as likely as white women to become pregnant, and the racial disparity persists even when donor eggs are used. These findings are being presented at the annual meeting of the American Society for Reproductive Medicine, held from Oct. 18 to 22 in Honolulu.
Hospital conversion to for-profit status is associated with improvements in financial margins, but has no effect on process quality metrics or mortality rates, according to a study published in the Oct. 22/29 issue of the Journal of the American Medical Association
Drinking sugar-sweetened sodas may affect cellular aging by shortening telomere length, according to research published online Oct. 16 in the American Journal of Public Health.
More Reading